Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase. A multikinase screen determined that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concentratio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Hexner, Elizabeth O., Serdikoff, Cynthia, Jan, Mahfuza, Swider, Cezary R., Robinson, Candy, Yang, Shi, Angeles, Thelma, Emerson, Stephen G., Carroll, Martin, Ruggeri, Bruce, Dobrzanski, Pawel
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2008
Ämnen:
Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2424161/
https://ncbi.nlm.nih.gov/pubmed/17984313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-083402
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk